| 今开：11.15 | 昨收：10.9 |
| 最高：11.24 | 最低：10.68 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：1.87540138E8 |
里格尔制药(RIGL)05-08 04:15
$里格尔制药(RIGL)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-24-007041 Act: 34 Size: 9 MB 网页链接查看全文
里格尔制药(RIGL)05-30 04:15
$里格尔制药(RIGL)$ 8-K Current report, items 5.02 and 5.07 Accession Number: 0001104659-24-066058 Act: 34 Size: 215 KB 网页链接查看全文
里格尔制药(RIGL)05-30 07:25
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-001656 Size: 6 KB 网页链接查看全文
里格尔制药(RIGL)05-30 07:25
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-001653 Size: 6 KB 网页链接查看全文
里格尔制药(RIGL)05-30 07:25
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-001654 Size: 6 KB 网页链接查看全文
里格尔制药(RIGL)06-25 20:55
$里格尔制药(RIGL)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-24-074574 Act: 34 Size: 233 KB 网页链接查看全文
里格尔制药(RIGL)06-28 04:35
$里格尔制药(RIGL)$ 8-K Current report, items 3.03, 5.03, and 9.01 Accession Number: 0001104659-24-075697 Act: 34 Size: 215 KB 网页链接查看全文
里格尔制药(RIGL)05-30 07:25
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-001651 Size: 6 KB 网页链接查看全文
里格尔制药(RIGL)05-08 04:25
$里格尔制药(RIGL)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-24-058017 Act: 34 Size: 337 KB 网页链接查看全文
里格尔制药(RIGL)05-30 07:25
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-001652 Size: 6 KB 网页链接查看全文
chuminhua2021-08-14 21:40
8月13日，FDA已经告诉Rigel Pharmaceuticals，Tavalisse，一种口服脾酪氨酸激酶（SKY）抑制剂，现在还不会获得紧急使用授权（EUA）。Rigel周五说，该药物现有的COVID-19数据，即在59名患者中进行的2期试验，是不够的。
Rigel公司正在进行一项更大的3期试验，正在积极招募病人。Rigel公司总裁兼...查看全文
jincen02082021-02-19 08:22
2月18日#BD交易# #礼来制药# #RIPK1抑制剂# ：
礼来与里格尔制药达成关于R552（一种RIPK1抑制剂）的合作签约，根据协议，礼来将向里格尔制药支付1.25亿美元预付款，未来还将支付8.35亿美元的商业里程金。
RIPK1是参多种细胞内炎症通路的关键蛋白，抑制RIPK1是潜在的针对各种自身免疫疾病...查看全文
Takeabreak2018-10-11 21:01
$Rigel Pharmaceuticals, Inc. (RIGL)$
EMA accepts Rigel's marketing application for fostamatinib for immune thrombocytopenia查看全文
智通财经APP获悉，Rigel制药公司(RIGL.US)周四表示，该公司用于治疗复发或难治性(R/R)急性髓系白血病(AML)患者的Rezlidhia(olutasidenib)胶囊已获美国食品药品监督管理局批准。Rigel称，这一批准得到了2期试验数据的支持。受此消息影响... 网页链接
智通财经APP获悉，H.C. Wainwright分析师Joseph Pantginis将Rigel Pharmaceuticals(RIGL.US)的目标价从8美元上调至11美元，维持“买入”评级。该公司此前公布了治疗COVID-19住院患者的Tavalisse (fostamatinib)的2期临床试验的积极结果... 网页链接
$里格尔制药(RIGL)$ 8-K Current report, items 3.03, 5.03, and 9.01 Accession Number: 0001104659-24-075697 Act: 34 Size: 215 KB 网页链接
$里格尔制药(RIGL)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-24-074574 Act: 34 Size: 233 KB 网页链接
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-001651 Size: 6 KB 网页链接
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-001652 Size: 6 KB 网页链接
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-001656 Size: 6 KB 网页链接
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-001653 Size: 6 KB 网页链接
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-001654 Size: 6 KB 网页链接
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-001655 Size: 6 KB 网页链接
$里格尔制药(RIGL)$ 8-K Current report, items 5.02 and 5.07 Accession Number: 0001104659-24-066058 Act: 34 Size: 215 KB 网页链接
$里格尔制药(RIGL)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-24-058017 Act: 34 Size: 337 KB 网页链接